FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311703384> ?p ?o ?g. }

• W4311703384 abstract "BackgroundPneumonia and bloodstream infections (BSI) due to extensively drug-resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem-resistant Enterobacterales (CRE) are associated with high mortality rates, and therapeutic options remain limited. This trial assessed whether combination therapy with colistin and meropenem was superior to colistin monotherapy for the treatment of these infections.MethodsThe OVERCOME (Colistin Monotherapy versus Combination Therapy) trial was an international, randomized, double-blind, placebo-controlled trial. We randomly assigned participants to receive colistin (5 mg/kg once followed by 1.67 mg/kg every 8 hours) in combination with either meropenem (1000 mg every 8 hours) or matching placebo for the treatment of pneumonia and/or BSI caused by XDR A. baumannii, XDR P. aeruginosa, or CRE. The primary outcome was 28-day mortality, and secondary outcomes included clinical failure and microbiologic cure.ResultsBetween 2012 and 2020, a total of 464 participants were randomly assigned to treatment, and 423 eligible patients comprised the modified intention-to-treat population. A. baumannii was the predominant trial pathogen (78%) and pneumonia the most common index infection (70%). Most patients were in the intensive care unit at the time of enrollment (69%). There was no difference in mortality (43 vs. 37%; P=0.17), clinical failure (65 vs. 58%; difference, 6.8 percentage points; 95% confidence interval [CI], −3.1 to 16.6), microbiologic cure (65 vs. 60%; difference, 4.8 percentage points; 95% CI, −5.6 to 15.2), or adverse events (acute kidney injury, 52 vs. 49% [P=0.55]; hypersensitivity reaction, 1 vs. 3% [P=0.22]; and neurotoxicity, 5 vs. 2% [P=0.29]) between patients receiving monotherapy and combination therapy, respectively.ConclusionsCombination therapy with colistin and meropenem was not superior to colistin monotherapy for the treatment of pneumonia or BSI caused by these pathogens. (Funded by the National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases protocol 10-0065; ClinicalTrials.gov number, NCT01597973.)" @default.
• W4311703384 created "2022-12-28" @default.
• W4311703384 creator A5003711145 @default.
• W4311703384 creator A5007426598 @default.
• W4311703384 creator A5010527305 @default.
• W4311703384 creator A5012057939 @default.
• W4311703384 creator A5012787385 @default.
• W4311703384 creator A5013028768 @default.
• W4311703384 creator A5013718821 @default.
• W4311703384 creator A5017259086 @default.
• W4311703384 creator A5023479710 @default.
• W4311703384 creator A5027243526 @default.
• W4311703384 creator A5029011028 @default.
• W4311703384 creator A5032987835 @default.
• W4311703384 creator A5033384686 @default.
• W4311703384 creator A5035946224 @default.
• W4311703384 creator A5036096072 @default.
• W4311703384 creator A5038285556 @default.
• W4311703384 creator A5044139066 @default.
• W4311703384 creator A5052142949 @default.
• W4311703384 creator A5054435941 @default.
• W4311703384 creator A5066972119 @default.
• W4311703384 creator A5069734398 @default.
• W4311703384 creator A5072009497 @default.
• W4311703384 creator A5072511384 @default.
• W4311703384 creator A5073576936 @default.
• W4311703384 creator A5074546960 @default.
• W4311703384 creator A5075004313 @default.
• W4311703384 creator A5075427091 @default.
• W4311703384 creator A5076910616 @default.
• W4311703384 creator A5077074926 @default.
• W4311703384 creator A5080813847 @default.
• W4311703384 creator A5084829703 @default.
• W4311703384 date "2023-01-01" @default.
• W4311703384 modified "2023-10-16" @default.
• W4311703384 title "Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms" @default.
• W4311703384 cites W2036496398 @default.
• W4311703384 cites W2071637551 @default.
• W4311703384 cites W2134377638 @default.
• W4311703384 cites W2139937737 @default.
• W4311703384 cites W2151069359 @default.
• W4311703384 cites W2618911885 @default.
• W4311703384 cites W2766370714 @default.
• W4311703384 cites W2786314763 @default.
• W4311703384 cites W2895593384 @default.
• W4311703384 cites W2911566892 @default.
• W4311703384 cites W2915553362 @default.
• W4311703384 cites W2966109951 @default.
• W4311703384 cites W2972837536 @default.
• W4311703384 cites W2975667851 @default.
• W4311703384 cites W3007887833 @default.
• W4311703384 cites W3009858064 @default.
• W4311703384 cites W3090322582 @default.
• W4311703384 cites W3090946937 @default.
• W4311703384 cites W3162278954 @default.
• W4311703384 cites W4200250437 @default.
• W4311703384 cites W4206677002 @default.
• W4311703384 cites W4224266833 @default.
• W4311703384 cites W4293242440 @default.
• W4311703384 doi "https://doi.org/10.1056/evidoa2200131" @default.
• W4311703384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37538951" @default.
• W4311703384 hasPublicationYear "2023" @default.
• W4311703384 type Work @default.
• W4311703384 citedByCount "14" @default.
• W4311703384 countsByYear W43117033842023 @default.
• W4311703384 crossrefType "journal-article" @default.
• W4311703384 hasAuthorship W4311703384A5003711145 @default.
• W4311703384 hasAuthorship W4311703384A5007426598 @default.
• W4311703384 hasAuthorship W4311703384A5010527305 @default.
• W4311703384 hasAuthorship W4311703384A5012057939 @default.
• W4311703384 hasAuthorship W4311703384A5012787385 @default.
• W4311703384 hasAuthorship W4311703384A5013028768 @default.
• W4311703384 hasAuthorship W4311703384A5013718821 @default.
• W4311703384 hasAuthorship W4311703384A5017259086 @default.
• W4311703384 hasAuthorship W4311703384A5023479710 @default.
• W4311703384 hasAuthorship W4311703384A5027243526 @default.
• W4311703384 hasAuthorship W4311703384A5029011028 @default.
• W4311703384 hasAuthorship W4311703384A5032987835 @default.
• W4311703384 hasAuthorship W4311703384A5033384686 @default.
• W4311703384 hasAuthorship W4311703384A5035946224 @default.
• W4311703384 hasAuthorship W4311703384A5036096072 @default.
• W4311703384 hasAuthorship W4311703384A5038285556 @default.
• W4311703384 hasAuthorship W4311703384A5044139066 @default.
• W4311703384 hasAuthorship W4311703384A5052142949 @default.
• W4311703384 hasAuthorship W4311703384A5054435941 @default.
• W4311703384 hasAuthorship W4311703384A5066972119 @default.
• W4311703384 hasAuthorship W4311703384A5069734398 @default.
• W4311703384 hasAuthorship W4311703384A5072009497 @default.
• W4311703384 hasAuthorship W4311703384A5072511384 @default.
• W4311703384 hasAuthorship W4311703384A5073576936 @default.
• W4311703384 hasAuthorship W4311703384A5074546960 @default.
• W4311703384 hasAuthorship W4311703384A5075004313 @default.
• W4311703384 hasAuthorship W4311703384A5075427091 @default.
• W4311703384 hasAuthorship W4311703384A5076910616 @default.
• W4311703384 hasAuthorship W4311703384A5077074926 @default.
• W4311703384 hasAuthorship W4311703384A5080813847 @default.
• W4311703384 hasAuthorship W4311703384A5084829703 @default.
• W4311703384 hasBestOaLocation W43117033841 @default.
• W4311703384 hasConcept C126322002 @default.
• W4311703384 hasConcept C141071460 @default.

• next